| Efficacy and safety of topical tazarotene: a review. | |
| | |
MedLine Citation:
|
PMID: 20213916 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris. OBJECTIVES: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders. METHODS: We reviewed the published literature available on PubMed for safety and efficacy of topical tazarotene gel or cream preparations. RESULTS/CONCLUSIONS: Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer. Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies. Daily application of tazarotene is effective with sustained benefits and limited local side effects. |
| | |
Authors:
|
Rakhashandra Talpur; Katherine Cox; Madeleine Duvic |
Related Documents
:
|
3912976 - The treatment of herpes zoster infections. 16265796 - Adaptation to bereavement. 15964746 - The use of atypical antipsychotics in the treatment of catatonia. 9601196 - Neurologic symptoms following pfiesteria exposure: case report and literature review. 15765046 - Stenosis of the abdominal aorta caused by fibromuscular dysplasia. 15083006 - Accident-induced late complaint of odontoid nonunion. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on drug metabolism & toxicology Volume: 5 ISSN: 1744-7607 ISO Abbreviation: Expert Opin Drug Metab Toxicol Publication Date: 2009 Feb |
Date Detail:
|
Created Date: 2010-03-08 Completed Date: 2010-05-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101228422 Medline TA: Expert Opin Drug Metab Toxicol Country: England |
Other Details:
|
Languages: eng Pagination: 195-210 Citation Subset: IM |
Affiliation:
|
University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA. rtalpur@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acne Vulgaris
/
drug therapy*,
physiopathology Administration, Cutaneous Animals Carcinoma, Basal Cell / drug therapy, pathology Dermatologic Agents / administration & dosage, adverse effects, therapeutic use* Humans Nicotinic Acids / administration & dosage, adverse effects, therapeutic use* Psoriasis / drug therapy*, physiopathology Receptors, Retinoic Acid / drug effects, genetics Skin Aging / drug effects Up-Regulation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Dermatologic Agents; 0/Nicotinic Acids; 0/RARRES3 protein, human; 0/Receptors, Retinoic Acid; 118292-40-3/tazarotene |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modification of Derzhavin sphyncteroplasty and elimination of symphysis diastasis of the pubic bone ...
Next Document: Using spatial occlusion to explore the control strategies used in rapid interceptive actions: Predic...